Guidelines & Consensus
Optimizing Primary Brain Tumor Clinical Trial Design: A Problem-Based Neuro-Oncology Framework
Gómez-Puerto et alFrontiers in Oncology
Primary brain tumor clinical trials frequently encounter interpretability and generalizability failures when critical development threats—including biological mismatch, inadequate drug penetration across the blood-brain barrier, restrictive eligibility, molecular rarity, unstable control cohorts, and endpoint ambiguity—are evaluated in isolation. A narrative synthesis encompassing methodological literature, regulatory guidance, consensus recommendations, and clinical trials through establishes a problem-based framework that systematically pairs dominant trial threats with prespecified methodological countermeasures across four core domains: problem identification, failure mode, design response, and residual uncertainty.
Analysis of published neuro-oncology trials highlights critical mechanisms underlying investigational failures and successes. Despite targeted biomarker selection, the ACT IV and INTELLANCE-1 studies failed to demonstrate an overall survival benefit in glioblastoma. Similarly, in CheckMate 143, durable minority immune responses failed to translate into statistically superior outcomes versus bevacizumab. Conversely, trials such as ROAR and INDIGO validate that clinical success requires a triad of robust biological selection, documented brain penetration, and appropriate disease positioning.
The synthesis also highlights that control benchmarks for recurrent glioblastoma demonstrate marked drift between historical and modern cohorts, rendering single-arm historical comparisons unreliable. To mitigate endpoint ambiguity, trial designs must structure comprehensive endpoint hierarchies that merge contemporary Response Assessment in Neuro-Oncology (RANO) criteria with overall survival, neurologic function, cognitive assessment, seizure activity, corticosteroid exposure thresholds, and patient-reported outcomes. Utilizing structured decision trees and auditable design rationales ensures that trial assumptions directly address disease-specific failure modes before advancing into definitive clinical evaluation.
Key Takeaways
- Biomarker selection alone failed to yield an overall survival benefit in ACT IV and INTELLANCE-1, while CheckMate 143 demonstrated that durable minority response signals did not translate to superior outcomes compared to bevacizumab.
- Findings from the ROAR and INDIGO trials demonstrate that pairing strong biological selection with brain-penetrant therapy in disease-appropriate cohorts can achieve clinically meaningful efficacy.
- Recurrent glioblastoma outcome benchmarks differ substantially between historical and contemporary control cohorts, establishing the necessity of accounting for control drift and integrating multidimensional endpoints including RANO criteria, cognition, and corticosteroid burden.
Read the original sourceFrontiers in Oncology
